STXS

Stereotaxis, Inc. 10-Q Summary: Period Ended June 30, 2007

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2007, and the six-month period ended on that date. Stereotaxis, Inc. designs, manufactures, and markets the NIOBE magnetic navigation system, an advanced cardiology instrument control system used to guide catheters and guidewires during interventional procedures for arrhythmias and coronary artery disease. The company operates primarily in the U.S., Europe, and Asia.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 105% for the quarter and 206% for the six-month period compared to the same periods in 2006. This was driven by a 102% increase in systems revenue (deliveries increased from 3 to 5 systems in Q2) and a 116% increase in disposables/service revenue due to a larger installed base.
• Inventory Impairment: Cost of revenue included a one-time $1.87 million impairment charge related to the first-generation Niobe 1 systems remaining in inventory. This charge significantly impacted gross margins for the period.
• Operating Expenses: Operating expenses increased across all categories. R&D expenses rose 28% (quarterly) due to development of 8mm and irrigated catheters. Sales and marketing expenses increased 22% due to expanded headcount and travel. G&A expenses rose 13% due to increased compensation costs.
• Financing Activity: In March 2007, the company completed a common stock offering raising approximately $20.1 million in net proceeds. Additionally, the company amended its credit agreement to increase borrowing capacity to $25 million and drew $2 million on an equipment loan.

Guidance, Outlook, and Risks

• Outlook: Management expects negative cash flow from operations to continue through 2007. Total operating expenses for the full year are expected to increase approximately 20% over 2006 expenditures to support sales growth and training capabilities.
• Liquidity: The company believes existing cash, investments, and available bank lines (~$13.3 million borrowing capacity) are sufficient to fund operations for the next 12 months. However, additional financing may be required, which could be dilutive.
• Backlog: Purchase orders and commitments for the magnetic navigation system were approximately $55 million as of June 30, 2007. Management notes that orders are subject to contingencies and may be revised or cancelled.
• Risks: Key risks include the need for additional capital, currency fluctuations (exposure to Euro), and the uncertainty of revenue recognition for backlog orders. The company has not hedged foreign currency exposure.
• Unusual Items: The $1.87 million inventory impairment charge is a non-recurring item affecting the current period's profitability.

Investor Verification Checklist

• Verify the sustainability of the 105% revenue growth rate and the conversion rate of the $55 million backlog into recognized revenue.
• Confirm the status of the $1.87 million inventory impairment and whether further write-downs of legacy Niobe 1 systems are anticipated.
• Monitor the burn rate of cash given the expectation of negative operating cash flow through 2007 and the potential need for dilutive equity financing.
• Review the progress of the 8mm and irrigated catheter development programs driving the increase in R&D expenses.
• Assess the impact of the amended credit agreement covenants, specifically the quick asset ratio requirement of 1.75 to 1.